Literature DB >> 30460452

Cardiac manifestations of Han Chinese patients with systemic lupus erythematosus: a retrospective study.

Ertao Jia1, Hongling Geng2, Qingping Liu3, Yuya Xiao4, Yanying Zhang4, Jingjing Xie4, Luhe Zhang3, Xia Qiu4, Li Zhong4, Min Xiao4, Jianyong Zhang5.   

Abstract

OBJECTIVE: To investigate cardiac manifestations and the risk factors in Han Chinese patients with systemic lupus erythematosus (SLE).
METHODS: Seven hundred fifty SLE patients who were hospitalized at our department were recruited in the present study. The patients were divided into two groups-those with or without cardiac manifestations. Cardiac manifestations in those SLE patients, such as pericarditis, myocarditis, heart valve disease, arrhythmia, were analyzed. The risk and protective factors of cardiac diseases in patients with SLE, as well as the predictors of mortality, were assessed, respectively.
RESULTS: In all 750 SLE patients, there were 339 (45.20%) patients suffered from one or more cardiac manifestations, involving pericarditis in 9.5%, myocarditis in 5.7%, heart valve disease in 15.6%, arrhythmia in 16.67%, and cardiovascular diseases (CVD) in 14%. 15.7% of SLE patients were accompanied with pulmonary arterial hypertension (PAH), of which 13.7% were mild, 1.2% were moderate, and 0.8% were severe. No significant differences were found between the two groups in age, disease duration, gender, antibody, and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). The incidence of pericarditis, heart valve disease, arrhythmia, and PAH was positively correlated with age. The incidence of arrhythmia, CVD, and PAH was correlated with SLEDAI. PAH and myocarditis were the risk factors of mortality in SLE patients with disease duration ≤ 10 years (P = 0.034 and 0.001, respectively).
CONCLUSION: Cardiac involvement is common in Han Chinese SLE patients and associated with age and disease activity. PAH and myocarditis are the risk factors of mortality in SLE.

Entities:  

Keywords:  Cardiac manifestations; Pulmonary arterial hypertension (PAH); Risk factor; Systemic lupus erythematosus (SLE)

Mesh:

Year:  2018        PMID: 30460452     DOI: 10.1007/s11845-018-1934-7

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  39 in total

1.  Assessment of echocardiographic abnormalities in patients with systemic lupus erythematosus: correlation with levels of antiphospholipid antibodies.

Authors:  R Gentile; B Laganà; L Tubani; M Casato; G M Ferri; F Fedele
Journal:  Ital Heart J       Date:  2000-07

2.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal
Journal:  Arthritis Rheum       Date:  2001-10

3.  Complete heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy.

Authors:  J Comín-Colet; M A Sánchez-Corral; J J Alegre-Sancho; J Valverde; D López-Gómez; X Sabaté; A Juan-Mas; E Esplugas
Journal:  Lupus       Date:  2001       Impact factor: 2.911

4.  Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus.

Authors:  Y Sherer; Y Levy; Y Shoenfeld
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

Review 5.  Cardiac involvement in systemic lupus erythematosus.

Authors:  K G Moder; T D Miller; H D Tazelaar
Journal:  Mayo Clin Proc       Date:  1999-03       Impact factor: 7.616

6.  Echocardiographic abnormalities and antiphospholipid antibodies in patients with systemic lupus erythematosus.

Authors:  Creso Abreu Falcao; Izabel Cristina Alves; Wiliam Habib Chahade; Angela Luzia Branco Pinto Duarte; Norma Lucena-Silva
Journal:  Arq Bras Cardiol       Date:  2002-09       Impact factor: 2.000

7.  Echocardiographic observation of acute myocarditis with systemic lupus erythematosus.

Authors:  T Ueda; K Mizushige; T Aoyama; M Tokuda; H Kiyomoto; H Matsuo
Journal:  Jpn Circ J       Date:  2000-02

8.  Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases.

Authors:  Pietro Enea Lazzerini; Maurizio Acampa; Francesca Guideri; Pier Leopoldo Capecchi; Valeria Campanella; Gabriella Morozzi; Mauro Galeazzi; Roberto Marcolongo; Franco Laghi-Pasini
Journal:  Arthritis Rheum       Date:  2004-04

9.  Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus.

Authors:  S Morelli; M L Bernardo; F Viganego; A Sgreccia; P De Marzio; F Conti; R Priori; G Valesini
Journal:  Lupus       Date:  2003       Impact factor: 2.911

10.  Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies.

Authors:  C A Roldan; B K Shively; C C Lau; F T Gurule; E A Smith; M H Crawford
Journal:  J Am Coll Cardiol       Date:  1992-11-01       Impact factor: 24.094

View more
  3 in total

1.  QRISK3-based analysis of cardiovascular risk factors in patients with long-term but well-controlled systemic lupus erythematosus.

Authors:  Shuo-Lin Wang; Wei Li; Tian-Fang Li; Xu Liang; Ye-Lan Yan; Sheng-Yun Liu
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

2.  Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.

Authors:  Enrico Ammirati; Emanuele Bizzi; Giacomo Veronese; Matthieu Groh; Caroline M Van de Heyning; Jukka Lehtonen; Marc Pineton de Chambrun; Alberto Cereda; Chiara Picchi; Lucia Trotta; Javid J Moslehi; Antonio Brucato
Journal:  Front Med (Lausanne)       Date:  2022-03-07

Review 3.  The spectrum of lupus myocarditis: from asymptomatic forms to cardiogenic shock.

Authors:  Maya Guglin; Carson Smith; Roopa Rao
Journal:  Heart Fail Rev       Date:  2020-11-19       Impact factor: 4.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.